The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy
- 31 May 1999
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 137 (5), S90-S93
- https://doi.org/10.1016/s0002-8703(99)70438-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) TrialCirculation, 1996
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)Journal of the American College of Cardiology, 1992
- Accelerated plasminogen activator dose regimens for coronary thrombolysisJournal of the American College of Cardiology, 1992
- In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparinThe Lancet, 1990
- From myocardial salvage to patient salvage in acute myocardial infarction: The role of reperfusion therapyJournal of the American College of Cardiology, 1989
- Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatorJournal of the American College of Cardiology, 1989
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985